Pacifica Pharmacy, Torrance, CA
Is Pacifica Pharmacy registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does Pacifica Pharmacy hold a California pharmacy license?
The California State Board of Pharmacy lists license PHY 39761 for Pacifica Pharmacy, Torrance, status Active, as of Nov 6, 2026.
Has Pacifica Pharmacy had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 state referral letter (Jul 8, 2020) and 1 FMD-145 letter (Jul 8, 2020) for Pacifica Pharmacy. State board actions: no California State Board of Pharmacy action on license PHY 39761 or under this exact name and city was found in the board’s posted disciplinary decisions on facility licenses (actions dated Jan 5, 2005 to Oct 28, 2026) on Nov 6, 2026. The state referral and handoff letters above are FDA’s letters to the state, not board actions.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Pacifica Pharmacy
- Location
- Torrance, CA
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 1
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- Jul 8, 2020
- FDA Data Dashboard inspections
- 1 inspection: 1 VAI; 1 published Form 483
- Form 483 text on this page
- 1 Form 483, 2 observations
- State board records
- License found: PHY 39761, Active
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Pacifica Pharmacy, a 503A facility, with 3 dated actions.
| Document | |||
|---|---|---|---|
| Jul 8, 2020 | FMD-145 letter | FMD-145 Letter Issued 07/08/2020 | FDA copy (archived) |
| Jul 8, 2020 | State referral letter | Referral Letter to the California State Board of Pharmacy Issued 07/08/2020 | FDA copy (archived) |
| Sep 9, 2019 | Form 483 | 483 Issued 09/09/2019 | fda.gov |
A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Pacifica Pharmacy, Torrance, CA (FEI number 3006078531), matched to this page by exact name, city and state. It lists 1 inspection: 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Sep 9, 2019 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3006078531 | 1101576 |
Form 483s FDA has published for this site
- Sep 9, 2019: Form 483 to Pacifica Pharmacy, published Nov 5, 2019. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483 for this site has 2 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Aug 26, 2019 to Sep 9, 2019: 2 observations
- Firm on the cover
- Pacifica Pharmacy, 23560 Madison St, Torrance, CA 90505-4708
- FEI number
- 3006078531
- Establishment type on the cover
- Compounding Pharmacy
- FDA district office on the cover
- 19701 Fairchild Irvine, CA 92612-2445
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
You produced hazardous drugs without providing adequate cleaning of work surfaces and cleaning of utensils to prevent cross-contamination.
Specifically,
The cleaning of hazardous drug product is not adequate. Your firm's cleaning between compounded products included only a wipe down of the compounding area/compounding hood witn <Redacted B4>. Your firm could not provide evidence that <Redacted B4> cleaned the hazardous drugs compounded at your firm. Additionally, you could provide no evidence that the detergents used to wash utensils and equipment remove the hazardous drug products you work with. The compounding area/compounding hood, utensils, and equipment are shared amongst all products (both hazardous drugs and non-hazardous drugs) at your pharmacy. Hazardous drugs compounded at your firm include Chloramphenicol, Methimazole, Diethylstibestrol, Leflunomide, Estradiol, Apomorphine, Tretinoin, Oxytocin, Fluconazole, and Finasteride.
Your firm did not provide adequate cleaning of the <Redacted B4> hoods used to compound all hazardous drugs and non-hazardous drugs with <Redacted B4> ingredients. ...
Observation 2
You used a non-pharmaceutical grade component in the formulation of a drug product.
Specifically,
Your firm used an expired ingredient to compound several topical prescriptions. Vitamin A Palmitate in Almond Oil lot <Redacted B4> expired on 01/01/2019. Additionally, this lot of Vitamin A's label indicates that it should be stored refrigerated. The Vitamin A was held at room temperature. This Vitamin A was used in the compounding of 21 prescription products in the last three months.
State board of pharmacy records
The California State Board of Pharmacy file dated Nov 6, 2026 lists these licenses under the same name, city and state as this pharmacy. Board file.
| License | Type as the board gives it | Name on the board record | City | Status |
|---|---|---|---|---|
| PHY 39761 | Retail Pharmacy | Pacifica Pharmacy | Torrance | Active |
What this covers: Facility license decisions from the board’s quarterly Disciplinary Actions pages (87 of 88 quarters had a facility section). These are final decisions; accusations filed and immediate protection orders are not included. Actions in the data are dated Jan 5, 2005 to Oct 28, 2026.
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- California State Board of Pharmacy license file
- California State Board of Pharmacy disciplinary records
Records last pulled Nov 15, 2026. Every entry links to the original public record.